Table 1.
Childhood Asthma Management Program Subset Study Population Characteristics
| Characteristic | Budesonide (n = 188) | Placebo (n = 274) | P Value |
|---|---|---|---|
| Age, yr | 9.0 ± 2.1 | 8.8 ± 2.1 | 0.28 |
| Sex | 0.88 | ||
| Male | 109 (58.0) | 162 (59.1) | |
| Female | 79 (42.0) | 112 (40.9) | |
| Race | 6.1 × 10−10* | ||
| White | 127 (67.6) | 235 (85.8) | |
| Black | 41 (21.8) | 39 (14.2) | |
| Hispanic | 20 (10.6) | 0 (0) | |
| Total eosinophil count, log10 | 0.79 ± 0.3 | 0.78 ± 0.3 | 0.70 |
| Child had atopic dermatitis and saw doctor | 0.75 | ||
| Yes | 133 (70.7) | 194 (70.8) | |
| No | 48 (25.5) | 66 (24.1) | |
| Not available | 7 (3.7) | 14 (5.1) | |
| Age at first asthma symptoms, yr | 3.06 ± 2.2 | 3.0 ± 2.6 | 0.83 |
| Household income | 0.14* | ||
| <$15,000 | 17 (9.0) | 10 (3.6) | |
| $15,000–29,000 | 30 (16.0) | 42 (15.3) | |
| $30,000–49,000 | 56 (29.8) | 96 (35.0) | |
| >$50,000 | 78 (41.5) | 117 (42.7) | |
| Decline response | 5 (2.7) | 8 (2.9) | |
| Don't know | 1 (0.5) | 0 (0.0) | |
| Seen doctor for hay fever | 0.69 | ||
| Yes | 76 (40.4) | 96 (35.0) | |
| No | 27 (14.4) | 40 (14.6) | |
| Missing | 85 (45.2) | 138 (50.4) | |
| Severity of asthma | 0.27 | ||
| Mild | 80 (42.6) | 132 (48.2) | |
| Moderate | 108 (57.4) | 142 (51.8) | |
| FEV1 PC20 meth, mg/ml | 1.82 ± 2.2 | 2.12 ± 2.5 | 0.18 |
| FEV1% predicted at baseline | 93.0 ± 13.2 | 95.4 ± 13.6 | 0.06 |
| FEV1% predicted at last follow-up | 96.8 ± 12.8 | 94.4 ± 14 | 0.06 |
| Changes of FEV1% predicted between baseline and follow-up | 4.1 ± 12.8 | −0.6 ± 12.9 | 2.8 × 10−4 |
Definition of abbreviation: PC20 meth = the provocative concentration of methacholine that results in a 20% drop in FEV1.
Data presented as n (%) or mean ± SD.
*
P value from Fisher’s exact test.